HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 HOTSPOT THERAPEUTICS, INC., Case No. 22-cv-04109-TSH
Plaintiff, ORDER RE: COUNTERCLAIM
DEFENDANT’S MOTION TO DISMISS
v. AND RELATED ADMINISTRATIVE
MOTIONS TO SEAL
NURIX THERAPEUTICS, INC., Re: Dkt. Nos. 56, 57, 59, 60, 61, 62 Defendant.
12 I. INTRODUCTION Pending before the Court are Plaintiff/Counterclaim Defendant HotSpot Therapeutics, Inc.’s (“HotSpot’s”) Motion to Dismiss Defendant Nurix Therapeutics, Inc.’s (“Nurix’s”) Counterclaims (ECF No. 57) pursuant to Federal Rule of Civil Procedure 12(b)(6) and related Administrative Motions to Seal (ECF Nos. 57, 60, and 61). On December 21, 2022, Defendant filed an Opposition. ECF No. 59. On December 28, 2022, Plaintiff filed a Reply. ECF No. 62. ECF No. 63. Having considered the parties’ positions and relevant legal authority, the Court GRANTS IN PART AND DENIES IN PART Plaintiff HotSpot’s Motion to Dismiss Nurix’s Counterclaims and…